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1. Introduction 
Historically, in ancient civilization, man had already imagined changes in the morphology, 
structure and function of the human body. Egyptian and Greco-Roman mythology provided 
examples of the metamorphoses sung by Homer and Ovid, symbolic incarnations of the 
“comedie humaine” with its strength, weakness, vices and virtues. The liver has been the 
noble organ, the organ of life from time immemorial-liver in English, Leber in German, 
derived from the verb to live. An Indian legend from the 12th century B.C recounts the 
power of Shiva, who xenotransplanted an elephant head onto a child induce the Indian god 
Gaesha.[1] In ancient China, Yue-Jen (407-310 B.B.) induced anesthesia lasting 3 days by “the 
absorption of extremely strong wine, opened up the chest of two soldiers and after 
examining them, exchanged their hearts and transplanted them”. The first reference to the 
concept of organ transplantation and replacement for therapeutic purposes appears to be 
Hua-To (136 to 208 A.D.) who replaced diseased organs with healthy ones in patients under 
anesthesia induced with a mixture of Indian hemp.  
Although attempts at transplantation date back to ancient times, the impetus for modern 
transplantation was World War II and Battle of Britain. Royal Air Force pilots often were 
severely burned when their planes crashed. The mortality rate associated with burns 
corresponds to the size of the area of the skin that has been injured and the survival rate can 
be improved if the burned skin is replaced. For this reason, British doctors, attempted skin 
transplantation from other human donors as a mode of therapy. However, these attempts 
were uniformly unsuccessful. The transplanted skin became necrotic and fell off over 
several days.[2] This problem led investigators in 1940s to study skin transplantation in 
animal models. It remained for Sir Peter Medawar in 1944 to establish that the failure of a 
skin graft to “take” was the result of a process later termed immunological rejection.[3] Later 
studies by Gowens in 1948 revealed that lymphocytes play a major role in transplant 
rejection.[4] In 1951, it was shown that cortisone therapy significantly prolonged survival of 
skin allograft.[5] In 1959, Schwartz and Dameshek reported drug-induced immune-tolerance 
using 6-mercaptopurine.[6] Later in 1961, Calne and Murray showed that azathioprine 
therapy suppressed the rejection reaction and prolonged allograft survival.[7]  
Once clinicians were confident that adequate immunosuppression was available, solid 
organ transplantation for end stage organ disease entered its early investigative phase. This 
was not possible without the application of the principles of vascular anastomosis pioneered 
by Alexis Carrel in 1902, for which he was awarded the Nobel Prize for Medicine in 1912.[8] 
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Further refinements in surgical techniques and suture materials have enabled Murray and 
his colleagues to perform the first successful kidney transplant in 1955.[9] This was a living 
donor transplant performed between identical twins. However, later attempts to perform 
renal transplantation when the donor and recipient were not genetically identical failed 
because no effective immunosuppressive therapy was available. From the early 1960s, a 
combination of azathioprine and corticosteroids was used with success to prevent graft 
rejection after kidney transplantation. In 1963, Woodraff described the immunosuppressive 
effect of antilymphocytic serum which destroyed the recipient active lymphocytes.[10] The 
success of kidney transplantation paved the way to think and perform liver transplantation 
for end-stage liver disease. 
In 1955, Welch reported on his efforts to transplant an auxiliary liver into the right 
paravertebral gutter of non-immunosuppressed mongrel dogs.[11] In 1958, Francis Moore 
described the standard technique of canine liver orthotopic liver transplantation.[12] In 
1963, Starzl attempted the first human orthotopic liver transplantation in a 3-years-old boy 
who suffered from biliary atresia, however, the patient died before the operation was 
completed.[13] Following this first unsuccessful attempt, the procedure evolved slowly and 
although his series remained largely unsuccessful, many of the technical principles that still 
guide liver transplantation were established. In 1967, Starzl and colleagues at the University 
of Colorado reported the first successful clinical liver transplantation.[14]  
Between 1966 and 1973, Starzl and colleagues performed three chimpanzee-to-human 
xenotransplantation of liver as well.[15] There have been 12 cases of clinical 
xenotransplantation including four cases of champazee-to-human, seven cases of baboon-to-
human and one case of pig-to-human.[16]  
In 1978, Roy Calne opened liver transplantation unit in Cambridge, UK, and performed the 
first liver transplantation in Europe and the second largest transplantation series in the 
world.[17] Until 1977, Starzl and Calne contributed the majority of performed liver 
transplantation worldwide.[18]  
The first hetero-topic liver transplants in man were reported by Apsolon in 1965; however, 
the first long-term survivor with this technique was reported by Fortner in 1973.[19]  
In 1984, Shaw et al introduced the venovenous bypass system at Pittsburg University, 
leading to better hemodynamic stability during the standard liver transplantation.[20]  
At the same time, Broelsch et al.[21] in the USA and Bismuth et al.[22] in France performed 
independently the first reduced-size liver transplantation. Thereafter, Pichlmayr et al.[23] 
reported the first split liver transplantation 1988. Meanwhile, Tzakis et al. introduced the 
piggyback technique with preservation of the recipient’s vena cava.[24] With the increasing 
number of the patients on the waiting list, transplantation of partial liver grafts from living 
donors evoluted to increase the donor pool. For this purpose, Broelsch et al. established the 
technique of segmental living donor liver transplantation (LDLT), and Strong et al. 
performed the first successful LDLT in 1989, implanting a left lateral segment into a 
pediatric patient.[25] In 1990, Broelsch et al. reported the first series of LDLT in the USA.[21] 
In 1991, the first domino liver transplantation using liver from donors affected by familial 
amyloidotic polyneuropathy type I was introduced by Holmgren at al.[26] In 1992, Belghiti 
and coworkers introduced a modified piggyback technique with a cavo-caval side-to-side 
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anastomosis.[27] One year later, Hashikura and colleagues transplanted a left hepatic lobe 
into an adult recipient in 1993,[28] and Yamaoka et al. implanted a right lobe into a pediatric 
recipient.[29] In 1996, Lo et al. performed the first successful liver transplantation using an 
extended right lobe from a living donor for an adult recipient.[30] In 1998, Tzakis et al. 
introduced liver transplantation with cavo-portal hemitransposition in the presence of 
diffuse portal vein thrombosis.[31] In 2002, Cherqui et al. reported first donor hepatectomy 
by a full laparoscopic procedure in which a left lateral lobectomy was successfully 
performed for liver transplantation in a child.[32] 
2. Evolution of immunosuppression 
Rejection of the transplant remained a major problem until cyclosporine-A was discovered 
by Jean Borel.[33] The 1-year survival rate following liver transplantation was 30% to 50% 
prior to the discovery of cyclosporine-A,[34,35] however, after the introduction of 
cyclosporine-A, the 1-year and 3-year survival rates were 74% and 67% in the first 1000 
recipients treated with cyclosporine-A at the University of Pittsburgh in the early 1980s.[36] 
After these good results, growth of liver transplantation was facilitated by the conclusion of 
the National Institute of Health Consensus Development Conference in 1983 that liver 
transplantation is not an experimental procedure but an effective therapy that deserves 
broader application.[34] Shortly thereafter, the first monoclonal antibody OKT3 was 
discovered by Cosimi in 1981 and proved effective in treating acute transplant rejection and 
was sometimes used along with cyclosporine-A based regimen as immunoprophylaxis 
especially in North American Centers or to treat steroid resistant graft rejection.[37] Since 
then, many new immunosuppressive agents were introduced. In 1990, Mycophenolate 
mofetil (MMF, CellCept) was introduced by University of Wisconsin and proved, in 
combination with cyclosporine-A, to further reduce the incidence of graft rejection episodes 
better than azathioprine with less toxic effects.[38] In the same year, Rapamycin (Sirolimus) 
was introduced.[39] It is like cyclosporine-A but it has a different mechanism of action. It 
inhibits lymphocyte proliferation through prevention of ligation of IL-2 to the IL-2 
receptors.[40] In 1994, Ochiai in Japan introduced tacrolimus (FK506, Prograf) and proved to 
reduce the incidence of transplant rejection more than cyclosporine A. It is like cyclosporine-
A but hundred times more potent and is indicated in severe acute rejection resistant to 
standard immunosuppressive protocols and in chronic rejection.[41] 
Greater understanding of the underlying liver disease, improved surgical and anaesthetic 
techniques, reliable immunosuppression and dependable postoperative care over the last 
few years have contributed towards improved results of liver transplantation. This success 
has resulted in a disproportionate increase in demand of liver transplantation and the 
appearance of a major problem of shortage of available donor organs, leading to a 
prolonged waiting times and high mortality on the waiting list.[42]  
3. The progress in liver transplantation with donor shortage 
The donor shortage together with the development of surgical skills of liver resections based 
on the knowledge of segmental anatomy of the liver described by Couinaud,[43] opened the 
door for innovative methods of transplantation including auxiliary liver transplantation, 
reduced-liver transplantation (RLT), split liver transplantation (SLT) and living donor liver  
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transplantation (LDLT).[44,45] Also, The donor shortage had led to the evolution of 
hepatocyte and stem cells transplantation which will be the future in the liver 
transplantation.  
3.1 Auxiliary liver transplantation 
Auxiliary liver transplantation (ALTx) consists of either implanting a healthy liver graft 
placed heterotopically or orthotopically while leaving all or part of the native liver. This 
concept was originated from an experimental work of Welch in 1955.[46, 47]  
The first auxiliary liver transplantation in human was performed by Absolon in 1964,[48] 
and it was till 1972 when an auxiliary transplantation truly prolonged a human life.[49] 
During the following two decades, ALTx was done solely in a heterotopic manner -
heterotopic auxiliary liver transplantation (HALTx), where a graft (usually partial) is placed 
below the un-resected native liver. The initial clinical results of HALTx were rather 
disappointing with a high rate of technical failure, probably due to inadequate portal 
perfusion of the graft and insufficient drainage of hepatic blood flow in an area of low 
pressure which had led to temporary abandonment of HALTx in the early 70s.[50-52]  
Many efforts have been made ever since to improve post-transplant survival. Most notably, 
based upon the experiences in animal studies,[52-58] the contributions of Terpstra’s group 
have improved the surgical techniques of HALTx with markedly increased post-HALTx 
survival rate.[58-63] Since 1980s’, the concept of ALTx has further been extended by the 
introduction of a new approach –auxiliary partial orthotopic liver transplantation 
(APOLTx), where the left or the right lobe of the native liver is resected and replaced by an 
auxiliary graft.[64-71] The physiological position of the hepatic graft by this approach results 
in an optimal outflow pressure. Accumulating clinical results have shown a reduced 
incidence of post-transplant portal thrombosis.[65, 72, 73] 
For certain types of non-cirrhotic metabolic disorders, such as type 1 Crigler-Najjar 
syndrome, urea cycle enzyme deficiencies, disorders of fatty acid metabolism, familial 
hypercholesterolemia, hemophilia and ornithine transcarbamylase deficiency, an auxiliary 
liver may correct the partial enzymatic deficiency responsible for the disease without the 
need to remove the otherwise normal native liver.[65, 66] A significant minority of patients 
with acute liver failure who fulfill the transplant criteria would have had complete 
morphological and functional recovery of their liver if they had not undergone orthotopic 
liver transplantation.[74] These considerations have led to the concept of auxiliary liver 
transplantation, which doesn’t exclude the potential for spontaneous regeneration of the 
native liver and eventual withdrawal of immunosuppression drugs.[75-78]  
In selected patient aged <40 years without hemodynamic instability, the use of ABO 
compatible, non-steatotic grafts harvested from young donors with normal liver function, 
can restore normal liver function and prevent the occurrence of irreversible brain damage. 
After standard immunosuppression, the recovery of the native liver is assessed by biopsies, 
hepatobiliary scintigraphy and computed tomography. When there is evidence of sufficient 
regeneration of the native liver, immunosuppression can be discontinued progressively. 
Complete regeneration of the native liver can be observed in >50% of patients, who can be 
withdrawn from immunosuppression. Therefore, the advantages of the auxiliary liver 
transplantation seem to balance with the potential inconvenience of this technique in 
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selected patients.[79-81] ALTx also preserves the patient’s native liver, which remains 
accessible for future gene transfer therapy.[82] 
3.2 Reduced-sized liver transplantation (RLT) 
It was first reported in 1984 by Bismuth, and involves ex-vivo resection of an adult cadaveric 
liver in order to create an appropriate sized liver graft for an infant or small child. It was 
introduced as a surgical solution for decreasing the pediatric liver transplant waiting list 
mortality using organs from donors much larger than the recipient, but does not increase 
the total number of livers available for transplantation. This is because the reduced-sized 
portion is not used and discarded.[22]  
Initially, RLT was criticized because it disadvantaged adult patients awaiting liver 
transplantation and was to be associated with inferior results. The allegations regarding 
inferior graft and patient survival were proven wrong,[83-85] and several proponents of this 
technique actually reported a lower incidence of vascular complications since the caliber of 
the hepatic artery was larger than that seen in a pediatric donor.[86] Since this technique 
resulted in discarding the remaining portion of liver, it clearly had a negative impact on 
adult population awaiting liver transplantation, and for that reason, is rarely used today. 
3.3 Split liver transplantation (SLT) 
In 1988, Pichlmayer in Germany and Bismuth in France simultaneously performed split liver 
transplantation (SLT), an ex-vivo splitting of a cadaveric liver allowing transplantation to a 
pediatric recipient and one adult.[23, 87] Unlike RLT, SLT resulted in an increased number 
of organs in donor pool with each cadaveric liver giving rise to two functioning allografts. 
The initial results of SLT, reported by Broelsch,[21] had a high rate of graft failure with a 
survival rate of only 67% in children and 20% in adults receiving a split liver transplants. In 
addition, 35% of patients required retransplantation and more than a quarter had biliary 
complications.[22] More recently, in-situ SLT has provided patient and graft survival similar 
to that seen in whole cadaveric transplantation.[88-90] The practical feasibility of split-liver 
transplantation as well as the increased safety of conventional liver surgery suddenly 
opened up the idea of removing part of the liver from a living donor. 
3.4 Living donor liver transplantation (LDLT) 
This has been made possible by recent advances in hepatic surgery; first, improved 
understanding of the anatomy and the techniques of hepatic resections,[91] second, growing 
evidence that the operative risk of partial hepatectomy in a non-cirrhotic liver is extremely 
low,[92, 93] third, widespread success with RLT,[25, 83-85, 94] and fourth, the successful 
application of SLT.[95] 
3.4.1 LDLT in pediatrics 
LDLT was first introduced in pediatric population. In 1988, Raia in Brazil reported the first 
LDLT, establishing the technical feasibility of this procedure, yet both pediatric recipients 
died of complications.[96] Strong and colleagues subsequently reported the first successful 
pediatric LDLT using a left lobe graft from the child’s mother.[25] Broelsch reported the first  
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successful series of LDLT with an overall graft survival of 75% and patient survival of 
85%.[97] Furthermore, he was the first to report a prospective ethical analysis of this radical 
surgical innovation prior to performing their first LDLT.[98]  
LDLT in children involves the removal of an adult donor left lateral segment (segment 2 and 
3). Monosegment transplantation (segment 3) was introduced in Japan to solve the problem 
of “Large for size” grafts in small children.[99] The donor operation has been associated 
with a low and acceptable risk for complications. The donors being related to the recipients 
(parents), the risk for the donor is balanced by the great benefit to be received by the 
transplant recipient, as well as the donor’s psychological benefit. 
LDLT was initially restricted to children with chronic disease, in relatively stable condition, 
in order to avoid a major psychological pressure on the potential donor.[98] With larger 
experience, it was extended to emergency cases such as fulminant hepatic failure. Auxiliary 
transplantation, initially developed in this indication,[78] and in metabolic disorders,[100] 
could also be performed with a living donor liver.[101-104] 
The continued shortage of cadaver livers in the face of growing list of recipients plus the 
advantages of LDLT have led to the introduction of LDLT in adults. 
3.4.2 Adult-to-adult LDLT 
The expansion of LDLT to the adult population began in the countries where the availability 
of deceased donors was scarce, and in some cases, totally unavailable.[105-107] The law for 
deceased organ retrieval was instituted in Japan in 1998, however, the lack of societal 
acceptance of organ retrieval from brain dead donors resulted in live donation being the 
main source of grafts for patients awaiting transplantation in Japan and other countries in 
Asia.[108] 
On November 2, 1993, the Shinshu group performed the first successful adult-to-adult 
LDLT.[28] By June 2002, there were 433 adult LDLT cases recorded in European Liver 
Transplantation Regestery,[109] with 3 years graft and patient survival rate of 65% and 68% 
respectively. According to the United Network for Organ Sharing (UNOS), 731 adult LDLT 
cases have been performed in the United States by October 2001. The 3 years graft survival 
was 47% between 1998 and 1999 (n=156) but it improved significantly to 61% between July 
1999 and June 2001 (n=285).[110] According to the Japanese Liver Transplantation Society, 
1063 adult LDLT procedures were performed in Japan by the end of 2002. The 5 years 
survival rates were 83% in children and 69% in adults.[111] The lesser outcome in adults 
compared to that in children indicates that problems remain in adult LDLT. 
In LDLT, donor safety must be assured. This may be achieved by optimizing graft size to 
ensure safety of both donor and recipient, technical expertise in liver procurement from 
the donor as well as ethical problems of using non-related live donors. As regarding the 
optimum size of the graft, it was found that, a graft volume of >40% of the recipient 
standard liver volume is necessary,[112] while for the living donor the remnant liver mass 
must be more than 30% of the whole liver.[113] The term “standard liver volume” has 
become a key concept in LDLT and it has been estimated using the following 
formula:[114] 
Standard liver volume (SV) in ml = 706.2 x (body surface area [m2]) + 2.4. 
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In order to obtain the optimum graft size in adult-to-adult living donor transplantation, 
many graft types has been introduced. The strategy of selection of left or right liver graft is 
influenced by the patient’s preoperative condition as patient with advanced liver disease 
require a larger liver mass.[115] The model for end-stage liver disease (MELD) score could 
become a satisfactory criterion for differentiating between high and low-risk patients and 
therefore determine the type of graft to use.[116] In the initial adult LDLT procedures only a 
left liver graft was used. In 1998, the Shinshu group reported satisfactory results using a left 
liver graft in 13 patients.[107] To cover wide range of recipient body weight, the right lobe 
graft was introduced in 1998 in Kyoto university.[117] In the same year, the University of 
Colorado group also introduced the right liver graft in adult LDLT,[118] the group performed 
80 adult LDLT. In the first 10 cases, the right lobe graft was procured without the middle 
hepatic vein (MHV), 3 grafts were lost. As a result, the group included the MHV in the right 
lobe graft in the subsequent 70 cases. No graft loss was experienced.[119] The reason may be 
due to the prevention of congestion of the anterior segment of the right lobe which is 
drained by the MHV. However, the right lobe graft including the MHV was first introduced 
by the Hong Kong group in 1996.[106] In this situation, the volume of the remnant liver 
should be at least greater than 30% and the anatomy of vein 4 must be precisely evaluated 
before this procedure is accepted. However, the outcome of initial 8 donors and recipients 
were not without complications, one recipient died and the recipients as well as the donors 
experienced high morbidity.[106] The next 92 patients subsequently received extended right 
liver grafts (right lobe graft including the MHV) with the following innovations: elimination 
of venovenous bypass from the routine protocol, preservation of segment 4 venous drainage 
for donors, venoplasty of MHV and right hepatic vein (RHV) into a single orifice for better 
venous return and easy vein reconstruction in recipients and preservation of the blood 
supply to the right hepatic ducts. Over time the mortality rate of recipient decrease from 
16% in the initial 50 cases to 0% in more recent patients.[120] 
Lee, aggressively reconstructed the MHV tributaries in right liver grafts without the MHV 
trunk and named this type of graft a modified right lobe graft.[121] Ghobrial, also 
recommended reconstruction of the MHV tributary veins when the RHV in the graft was 
<1.5 cm in diameter.[90] All MHV tributaries with a size >5 mm should be preserved during 
donor hepatectomy and reconstructed with autogenous interposition vein grafts.[122] 
Right hepatectomy imposes an increased surgical risk on the donor due to the reduced 
residual liver volume. A recent report indicated that in 25% of potential donors, the right 
liver had an estimated volume of >70% of the whole.[123] Since safe donation was possible 
only when estimated residual liver volume was >30%, right hepatectomy is not possible for 
some potential donors. The University of Tokyo group was the first to design the right 
lateral sector graft consisting of segment 6 and 7 in those donors with right livers over 70% 
of liver volume and the estimated volume of the right lateral segments is greater than that of 
the left liver and at the same time >40% of the recipient’s standard liver volume.[124] 
Between January 2000 and April 2001, 6 of 32 adult-to-adult LDLT with a right lateral sector 
graft were performed. The postoperative course was uneventful in all donors and all 
recipients survived the operation.[125]  
Lee et al, were the first to devise dual grafts from 2 living donors.[126] Most commonly, 
both donors donate the left liver or left lateral segment. The first left liver graft is 
orthotopically implanted in the original left position, the second left liver graft is rotated 180 
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degrees and positioned heterotopically in the right upper quadrant fossa. Because the bile 
duct is now located behind the portal vein and hepatic artery, bile duct reconstruction is 
necessary before reconstruction of vessels. An interposition vein graft might be necessary 
for the reconstruction of the hepatic or portal vein. By the end of 2003, this technique was 
used in 93 patients with satisfactory results. However the procedure has limited appeal due 
to the high requirements of economic and medical resources including 3 operating rooms 
and 3 surgical teams working simultaneously.[127]  
4. Hepatocyte and stem cells transplantation 
Additional approaches, as therapeutic alternative in attempt to reduce the significant 
mortality in the waiting list for liver transplantation is hepatocyte transplantation. A 
number of experiments have shown the feasibility of total liver parenchymal cell 
replacement by transplanted hepatocytes.[128-132] Hepatocyte transplantation might be 
able to bridge a period needed for regeneration of the acute liver failure patient’s own liver 
or stretch the waiting time for a suitable liver donation. Although the first animal 
experiments with this technique began in 1967 [133], it was first applied in humans only in 
1992.[134] Isolated Hepatocyte transplantation has long been recognized as a potential 
treatment for life-threatening liver disease. The basis for proceeding with clinical trials has 
been provided by extensive laboratory work in animal models.[135-140] The most important 
advantage of this treatment compared to liver transplantation, is its simplicity, since no 
surgery is required for cell implantation. The cell transplantation has been used for, 
temporary metabolic support of patients in end-stage liver failure awaiting whole-organ 
transplantation, as method to support liver function and facilitate the regeneration of the 
native liver in cases of fulminant hepatic failure, and in a manner similar to gene therapy as 
a form of “cellular therapy” for patients with genetic defects in vital liver functions. The 
patients can be treated by the infusion of 107-1010 allogenic hepatocytes, obtained from adult 
cadaveric livers, into the splenic artery or portal vein.[141] The main obstacle to wider usage 
of hepatocyte transplantation is the rapid elimination of the transplanted hepatocytes by 
recipient macrophages.[142] 
Alternatives to the transplantation of allogenic human hepatocytes include the transplantation 
of hepatocytes derived from fetal, adult, or embryonic stem cells, engineered immortalized 
cells, or hepatocytes derived from other animal species.[143] Stem cells are one of the best 
approaches to obtaining cell stores. This approach can be used for clinical treatment by 
selecting small cell population that could effectively repopulate the host liver.[144] 
5. References 
[1] Calne R. The history and development of organ transplantation: biology and rejection. 
Bailliere's clinical gastroenterology. 1994 Sep;8(3):389-97. 
[2] Hansen TH, Carreno BM, Sachs DH. The major histocompatibility complex. In: Paul WE, 
ed. Fundamental immunology. New York: Raven Press 1993:577-628. 
[3] Medawar P. The behavior and fate of skin autografts and skin homografts in rabbits.  
J Anat. 1944;78:176. 
[4] Gowen JW. Inheritance of immunity in animals. Ann Rev Microbial. 1948;2:215. 
[5] Billingham RE, Krohn PL, Medawar PB. Effect of cortisone on survival of skin 
homografts in rabbits. Br Med J. 1951 May 26;4716:1157-63. 
www.intechopen.com
 
History and Evolution of Liver Transplantation 
 
11 
[6] Schwartz R, Stack J, Dameshek W. Effect of 6-mercaptopurine on antibody production. 
Proc Soc Exp Biol Med. 1958 Oct;99(1):164-7. 
[7] Calne RY, Murray JE. Inhibition of the rejection of renal homografts in dogs by 
Burroughs Wellcome 57-322. Surg Forum. 1961;12:118-20. 
[8] Carrel A. La technique opertoire des anastomoses vasculaires et la transplantation des 
visceres. Lyon Med. 1902;98:859. 
[9] Murray JE, Merrill JP, et al. Renal homotransplantation in identical twins. Surg Forum. 
1955;6:432. 
[10] Woodruff MF, Anderson NA. Effect of Lymphocyte Depletion by Thoracic Duct Fistula 
and Administration of Antilymphocytic Serum on the Survival of Skin Homografts 
in Rats. Nature. 1963 Nov 16;200:702. 
[11] Welch CS. A note on transplantation of the whole liver in dogs. Transplant Bull. 
1955;2:54. 
[12] Moore FD, Wheele HB, Demissianos HV, Smith LL, Balankura O, Abel K, et al. 
Experimental whole-organ transplantation of the liver and of the spleen. Ann Surg. 
1960 Sep;152:374-87. 
[13] Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. 
Homotransplantation of the Liver in Humans. Surgery, gynecology & obstetrics. 
1963 Dec;117:659-76. 
[14] Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, et al. Orthotopic 
homotransplantation of the human liver. Ann Surg. 1968 Sep;168(3):392-415. 
[15] Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ. The use of heterologous 
antilymphoid agents in canine renal and liver homotransplantation and in human 
renal homotransplantation. Surgery, gynecology & obstetrics. 1967 Feb;124(2):301-
8. 
[16] Taniguchi S, Cooper DKC (1997). Clinical xenotransplantation: a brief review of the 
world experience. In: Cooper DKC, Kemp E, Platt JL, White DJD (eds) 
Xenotransplantation: the transplantation of organs between species. Springer, 
Berlin Heidelberg New York, p779. 
[17] Calne RY, White DJ, Rolles K, Smith DP, Herbertson BM. Prolonged survival of pig 
orthotopic heart grafts treated with cyclosporin A. Lancet. 1978 Jun 3;1(8075):1183-5. 
[18] Eghtesad B, Kadry Z, Fung J. Technical considerations in liver transplantation: what a 
hepatologist needs to know (and every surgeon should practice). Liver Transpl. 
2005 Aug;11(8):861-71. 
[19] Fortner JG, Kinne DW, Shiu MH, Howland WS, Kim DK, Castro EB, et al. Clinical liver 
heterotopic (auxiliary) transplantation. Surgery. 1973 Nov;74(5):739-51. 
[20] Shaw BW, Jr., Martin DJ, Marquez JM, Kang YG, Bugbee AC, Jr., Iwatsuki S, et al. 
Venous bypass in clinical liver transplantation. Ann Surg. 1984 Oct;200(4):524-34. 
[21] Broelsch CE, Emond JC, Whitington PF, Thistlethwaite JR, Baker AL, Lichtor JL. 
Application of reduced-size liver transplants as split grafts, auxiliary orthotopic 
grafts, and living related segmental transplants. Ann Surg. 1990 Sep;212(3):368-75; 
discussion 75-7. 
[22] Bismuth H, Houssin D. Reduced-sized orthotopic liver graft in hepatic transplantation 
in children. Surgery. 1984 Mar;95(3):367-70. 
[23] Pichlmayr R, Ringe B, Gubernatis G, Hauss J, Bunzendahl H. [Transplantation of a 
donor liver to 2 recipients (splitting transplantation)--a new method in the further 
development of segmental liver transplantation]. Langenbecks Arch Chir. 
1988;373(2):127-30. 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
12 
[24] Tzakis A, Todo S, Starzl TE. Orthotopic liver transplantation with preservation of the 
inferior vena cava. Ann Surg. 1989 Nov;210(5):649-52. 
[25] Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver 
transplantation from a living donor to her son. N Engl J Med. 1990 May 
24;322(21):1505-7. 
[26] Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical 
effect of liver transplantation in two Swedish patients with familial amyloidotic 
polyneuropathy (FAP-met30). Clin Genet. 1991 Sep;40(3):242-6. 
[27] Belghiti J, Panis Y, Sauvanet A, Gayet B, Fekete F. A new technique of side to side caval 
anastomosis during orthotopic hepatic transplantation without inferior vena caval 
occlusion. Surgery, gynecology & obstetrics. 1992 Sep;175(3):270-2. 
[28] Hashikura Y, Makuuchi M, Kawasaki S, Matsunami H, Ikegami T, Nakazawa Y, et al. 
Successful living-related partial liver transplantation to an adult patient. Lancet. 
1994 May 14;343(8907):1233-4. 
[29] Yamaoka Y, Washida M, Honda K, Tanaka K, Mori K, Shimahara Y, et al. Liver 
transplantation using a right lobe graft from a living related donor. 
Transplantation. 1994 Apr 15;57(7):1127-30. 
[30] Lo CM, Fan ST, Liu CL, Lo RJ, Lau GK, Wei WI, et al. Extending the limit on the size of 
adult recipient in living donor liver transplantation using extended right lobe graft. 
Transplantation. 1997 May 27;63(10):1524-8. 
[31] Tzakis AG, Kirkegaard P, Pinna AD, Jovine E, Misiakos EP, Maziotti A, et al. Liver 
transplantation with cavoportal hemitransposition in the presence of diffuse portal 
vein thrombosis. Transplantation. 1998 Mar 15;65(5):619-24. 
[32] Cherqui D, Soubrane O, Husson E, Barshasz E, Vignaux O, Ghimouz M, et al. 
Laparoscopic living donor hepatectomy for liver transplantation in children. 
Lancet. 2002 Feb 2;359(9304):392-6. 
[33] Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, et al. In vivo 
pharmacological effects of ciclosporin and some analogues. Adv Pharmacol. 
1996;35:115-246. 
[34] National Institutes of Health Consensus Development Conference Statement: liver 
transplantation--June 20-23, 1983. Hepatology (Baltimore, Md. 1984 Jan-Feb;4(1 
Suppl):107S-10S. 
[35] Scharschmidt BF. Human liver transplantation: analysis of data on 540 patients from 
four centers. Hepatology (Baltimore, Md. 1984 Jan-Feb;4(1 Suppl):95S-101S. 
[36] Iwatsuki S, Starzl TE, Todo S, Gordon RD, Esquivel CO, Tzakis AG, et al. Experience in 
1,000 liver transplants under cyclosporine-steroid therapy: a survival report. 
Transplant Proc. 1988 Feb;20(1 Suppl 1):498-504. 
[37] Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, et al. Use of 
monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment 
in recipients of renal allografts. N Engl J Med. 1981 Aug 6;305(6):308-14. 
[38] Barry JM. Immunosuppressive drugs in renal transplantation. A review of the regimens. 
Drugs. 1992 Oct;44(4):554-66. 
[39] Strepkowski SM. Sirolimus, a potent new immunosuppressive drug for organ 
transplantation. Ann Transplant. 1996;1 (3):19-25. 
[40] Klagehpour K, Pyronnet S, Gingras AC, al e. Translational homeostasis: eukaryotic 
translation initiation factor 4E control of 4E-binding protien 1 and p70 s6 kinase 
activities. Mol Cell Biol. 1999;19:4302-20. 
www.intechopen.com
 
History and Evolution of Liver Transplantation 
 
13 
[41] Takada Y, Ueda M, Ishikawa Y, Fujimoto Y, Miyauchi H, Ogura Y, et al. End-to-side 
portocaval shunting for a small-for-size graft in living donor liver transplantation. 
Liver Transpl. 2004 Jun;10(6):807-10. 
[42] Modan B, Shpilberg O, Baruch Y, Sikuler E, Anis E, Ashur Y, et al. The need for liver 
transplantation: a nationwide estimate based on consensus review. Lancet. 1995 
Sep 9;346(8976):660-2. 
[43] Couinaud C. Le foie. Etudes anatomiques et chirurgicales. Paris: Masson. 1957. 
[44] Smith B. Segmental liver transplantation from a living donor. J Pediatr Surg. 1969 
Feb;4(1):126-32. 
[45] Dagradi A, Marzoli GP, Radin S, Sussi PL, Dagradi V, Zannini M, et al. [Possibilities of 
sectional liver transplantation in man]. Langenbecks Arch Chir. 1968;322:533-7. 
[46] Marchioro TL, Porter KA, Dickinson TC, Faris TD, Starzi TE. Physiologic Requirements 
for Auxiliary Liver Homotransplantation. Surgery, gynecology & obstetrics. 1965 
Jul;121:17-31. 
[47] Nagashima I, Bergmann L, Schweizer R. How can we share the portal blood inflow in 
auxiliary partial heterotopic liver transplantation without portal hypertension? 
Surgery. 1994 Jul;116(1):101-6. 
[48] Zhao D, Zimmermann A, Kuznetsova LV, Wheatley AM. Regression of bile duct 
damage and bile duct proliferation in the non-rearterialized transplanted rat liver is 
associated with spontaneous graft rearterialization. Hepatology (Baltimore, Md. 
1995 May;21(5):1353-60. 
[49] Svensson G, Naredi P, Hafstrom L, Tufveson G. Quantitative measurements of 
collateral arterial blood flow in nonarterialized rat liver grafts. Transpl Int. 
1994;7(2):136-9. 
[50] Howden B, Jablonski P, Grossman H, Marshall VC. The importance of the hepatic artery 
in rat liver transplantation. Transplantation. 1989 Mar;47(3):428-31. 
[51] Sumimoto R, Shinomiya T, Yamaguchi A. Influence of hepatic arterial blood flow in rats 
with liver transplants. Examination of donor liver-derived serum class I MHC 
antigen in rats with liver transplants with or without hepatic arterial 
reconstruction. Transplantation. 1991 May;51(5):1138-9. 
[52] Post S, Menger MD, Rentsch M, Gonzalez AP, Herfarth C, Messmer K. The impact of 
arterialization on hepatic microcirculation and leukocyte accumulation after liver 
transplantation in the rat. Transplantation. 1992 Nov;54(5):789-94. 
[53] Taub R. Liver regeneration 4: transcriptional control of liver regeneration. Faseb J. 1996 
Mar;10(4):413-27. 
[54] Gentile JM, Grace JT, Jr. A cell growth stimulating factor in partially hepatectomized rat 
serum. Surgical forum. 1968;19:62-3. 
[55] Morley CG, Kingdon HS. The regulation of cell growth. I. Identification and partial 
characterization of a DNA synthesis stimulating factor from the serum of partially 
hepatectomized rats. Biochimica et biophysica acta. 1973 May 10;308(2):260-75. 
[56] Michalopoulos GK, DeFrances MC. Liver regeneration. Science (New York, NY. 1997 
Apr 4;276(5309):60-6. 
[57] LaBrecque D. Liver regeneration: a picture emerges from the puzzle. The American 
journal of gastroenterology. 1994 Aug;89(8 Suppl):S86-96. 
[58] Moolten FL, Oakman NJ, Bucher NL. Accelerated response of hepatic DNA synthesis to 
partial hepatectomy in rats pretreated with growth hormone or surgical stress. 
Cancer research. 1970 Sep;30(9):2353-7. 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
14 
[59] Zhao D, Zimmermann A, Wheatley AM. Morphometry of the liver after liver 
transplantation in the rat: significance of an intact arterial supply. Hepatology 
(Baltimore, Md. 1993 Feb;17(2):310-7. 
[60] Burdelski M, Rogiers X. Liver transplantation in metabolic disorders. Acta gastro-
enterologica Belgica. 1999 Jul-Sep;62(3):300-5. 
[61] Kren BT, Trembley JH, Fan G, Steer CJ. Molecular regulation of liver regeneration. 
Annals of the New York Academy of Sciences. 1997 Dec 31;831:361-81. 
[62] Morsiani E, Aleotti A, Ricci D. Haemodynamic and ultrastructural observations on the 
rat liver after two-thirds partial hepatectomy. Journal of anatomy. 1998 May;192 ( 
Pt 4):507-15. 
[63] Zhang XK, Gauthier T, Burczynski FJ, Wang GQ, Gong YW, Minuk GY. Changes in 
liver membrane potentials after partial hepatectomy in rats. Hepatology (Baltimore, 
Md. 1996 Mar;23(3):549-51. 
[64] Neuschwander-Tetri BA, Nicholson C, Wells LD, Tracy TF, Jr. Cholestatic liver injury 
down-regulates hepatic glutathione synthesis. The Journal of surgical research. 
1996 Jul 1;63(2):447-51. 
[65] Chandler JG, Lee S, Krubel R, Rosen H, Nakaji NT, Orloff MJ. The inter-liver 
competition and portal blood in regeneration of auxiliary liver transplants. Surgical 
forum. 1971;22:341-3. 
[66] Shaw BW, Jr. Auxiliary liver transplantation for acute liver failure. Liver Transpl Surg. 
1995 May;1(3):194-200. 
[67] Wondergem R, Potter VR. A new protocol for studying the early events during liver 
regeneration. Life sciences. 1978 Oct 16;23(15):1565-75. 
[68] Schenk DB, Hubert JJ, Leffert HL. Use of a monoclonal antibody to quantify (Na+,K+)-
ATPase activity and sites in normal and regenerating rat liver. The Journal of 
biological chemistry. 1984 Dec 10;259(23):14941-51. 
[69] Moule SK, McGivan JD. Regulation of the plasma membrane potential in hepatocytes--
mechanism and physiological significance. Biochimica et biophysica acta. 1990 Oct 
8;1031(3):383-97. 
[70] Kelm M, Feelisch M, Deussen A, Strauer BE, Schrader J. Release of endothelium derived 
nitric oxide in relation to pressure and flow. Cardiovascular research. 1991 
Oct;25(10):831-6. 
[71] Feelisch M, Ostrowski J, Noack E. On the mechanism of NO release from sydnonimines. 
Journal of cardiovascular pharmacology. 1989;14 Suppl 11:S13-22. 
[72] Schoen JM, Wang HH, Minuk GY, Lautt WW. Shear stress-induced nitric oxide release 
triggers the liver regeneration cascade. Nitric Oxide. 2001;5(5):453-64. 
[73] Lambotte L, Saliez A, Triest S, Tagliaferri EM, Barker AP, Baranski AG. Control of rate 
and extent of the proliferative response after partial hepatectomy. The American 
journal of physiology. 1997 Oct;273(4 Pt 1):G905-12. 
[74] Wolf HK, Michalopoulos GK. Hepatocyte regeneration in acute fulminant and 
nonfulminant hepatitis: a study of proliferating cell nuclear antigen expression. 
Hepatology (Baltimore, Md. 1992 Apr;15(4):707-13. 
[75] Moritz MJ, Jarrell BE, Munoz SJ, Maddrey WC. Regeneration of the native liver after 
heterotopic liver transplantation for fulminant hepatic failure. Transplantation. 
1993 Apr;55(4):952-4. 
[76] Moritz MJ, Jarrell BE, Armenti V, Radomski J, Carabasi RA, Zeitoun G, et al. 
Heterotopic liver transplantation for fulminant hepatic failure--a bridge to 
recovery. Transplantation. 1990 Sep;50(3):524-6. 
www.intechopen.com
 
History and Evolution of Liver Transplantation 
 
15 
[77] Gubernatis G, Pichlmayr R, Kemnitz J, Gratz K. Auxiliary partial orthotopic liver 
transplantation (APOLT) for fulminant hepatic failure: first successful case report. 
World J Surg. 1991 Sep-Oct;15(5):660-5; discussion 5-6. 
[78] Boudjema K, Jaeck D, Simeoni U, Bientz J, Chenard MP, Brunot P. Temporary auxiliary 
liver transplantation for subacute liver failure in a child. Lancet. 1993 Sep 
25;342(8874):778-9. 
[79] Durand F, Belghiti J, Handra-Luca A, Francoz C, Sauvanet A, Marcellin P, et al. 
Auxiliary liver transplantation for fulminant hepatitis B: results from a series of six 
patients with special emphasis on regeneration and recurrence of hepatitis B. Liver 
Transpl. 2002 Aug;8(8):701-7. 
[80] Belghiti J, Sommacale D, Dondero F, Zinzindohoue F, Sauvanet A, Durand F. Auxiliary 
liver transplantation for acute liver failure. HPB (Oxford). 2004;6(2):83-7. 
[81] Chenard-Neu MP, Boudjema K, Bernuau J, Degott C, Belghiti J, Cherqui D, et al. 
Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 
patients with fulminant hepatic failure--a multicenter European study. Hepatology 
(Baltimore, Md. 1996 May;23(5):1119-27. 
[82] Nakazawa H, Genka C, Fujishima M. Pathological aspects of active oxygens/free 
radicals. The Japanese journal of physiology. 1996 Feb;46(1):15-32. 
[83] Emond JC, Whitington PF, Thistlethwaite JR, Alonso EM, Broelsch CE. Reduced-size 
orthotopic liver transplantation: use in the management of children with chronic 
liver disease. Hepatology (Baltimore, Md. 1989 Nov;10(5):867-72. 
[84] Ryckman FC, Flake AW, Fisher RA, Tchervenkov JI, Pedersen SH, Balistreri WF. 
Segmental orthotopic hepatic transplantation as a means to improve patient 
survival and diminish waiting-list mortality. J Pediatr Surg. 1991 Apr;26(4):422-7; 
discussion 7-8. 
[85] Otte JB, de Ville de Goyet J, Sokal E, Alberti D, Moulin D, de Hemptinne B, et al. Size 
reduction of the donor liver is a safe way to alleviate the shortage of size-matched 
organs in pediatric liver transplantation. Ann Surg. 1990 Feb;211(2):146-57. 
[86] Houssin D, Soubrane O, Boillot O, Dousset B, Ozier Y, Devictor D, et al. Orthotopic liver 
transplantation with a reduced-size graft: an ideal compromise in pediatrics? 
Surgery. 1992 May;111(5):532-42. 
[87] Bismuth H, Morino M, Castaing D, Gillon MC, Descorps Declere A, Saliba F, et al. 
Emergency orthotopic liver transplantation in two patients using one donor liver. 
Br J Surg. 1989 Jul;76(7):722-4. 
[88] Rogiers X, Malago M, Gawad K, Jauch KW, Olausson M, Knoefel WT, et al. In situ 
splitting of cadaveric livers. The ultimate expansion of a limited donor pool. Ann 
Surg. 1996 Sep;224(3):331-9; discussion 9-41. 
[89] Busuttil RW, Goss JA. Split liver transplantation. Ann Surg. 1999 Mar;229(3):313-21. 
[90] Goss JA, Yersiz H, Shackleton CR, Seu P, Smith CV, Markowitz JS, et al. In situ splitting 
of the cadaveric liver for transplantation. Transplantation. 1997 Sep 27;64(6):871-7. 
[91] Bismuth H, Castaing D, Garden OJ. Segmental surgery of the liver. Surg Annu. 
1988;20:291-310. 
[92] Iwatsuki S, Todo S, Starzl TE. Excisional therapy for benign hepatic lesions. Surgery, 
gynecology & obstetrics. 1990 Sep;171(3):240-6. 
[93] Bismuth H, Houssin D, Michel F. [Operative risk in hepatectomies. Experience with 154 
hepatectomies]. Chirurgie. 1983;109(4):342-8. 
[94] Kalayouglu M, D' Alessandro AM, Sollinger HW, et al. Experience with reduced-size 
liver transplantation. Surgery, gynecology & obstetrics. 1990;171:139-47. 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
16 
[95] Emond JC, Whitington PF, Thistlethwaite JR, Cherqui D, Alonso EA, Woodle IS, et al. 
Transplantation of two patients with one liver. Analysis of a preliminary 
experience with 'split-liver' grafting. Ann Surg. 1990 Jul;212(1):14-22. 
[96] Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet. 1989 Aug 
26;2(8661):497. 
[97] Broelsch CE, Whitington PF, Emond JC, Heffron TG, Thistlethwaite JR, Stevens L, et al. 
Liver transplantation in children from living related donors. Surgical techniques 
and results. Ann Surg. 1991 Oct;214(4):428-37; discussion 37-9. 
[98] Singer PA, Siegler M, Whitington PF, Lantos JD, Emond JC, Thistlethwaite JR, et al. 
Ethics of liver transplantation with living donors. N Engl J Med. 1989 Aug 
31;321(9):620-2. 
[99] Kasahara M, Kiuchi T, Haga H, Uemoto S, Uryuhara K, Fujimoto Y, et al. 
Monosegmental living-donor liver transplantation for infantile hepatic 
hemangioendothelioma. J Pediatr Surg. 2003 Jul;38(7):1108-11. 
[100] Whitington PF, Emond JC, Heffron T, Thistlethwaite JR. Orthotopic auxiliary liver 
transplantation for Crigler-Najjar syndrome type 1. Lancet. 1993 Sep 
25;342(8874):779-80. 
[101] Emond JC, Heffron TG, Kortz EO, Gonzalez-Vallina R, Contis JC, Black DD, et al. 
Improved results of living-related liver transplantation with routine application in 
a pediatric program. Transplantation. 1993 Apr;55(4):835-40. 
[102] Inomata Y, Kiuchi T, Kim I, Uemoto S, Egawa H, Asonuma K, et al. Auxiliary partial 
orthotopic living donor liver transplantation as an aid for small-for-size grafts in 
larger recipients. Transplantation. 1999 May 27;67(10):1314-9. 
[103] Yazaki M, Ikeda S, Takei Y, Yanagisawa N, Matsunami H, Hashikura Y, et al. 
Complete neurological recovery of an adult patient with type II citrullinemia after 
living related partial liver transplantation. Transplantation. 1996 Dec 
15;62(11):1679-84. 
[104] Kasahara M, Kiuchi T, Uryuhara K, Ogura Y, Takakura K, Egawa H, et al. Treatment of 
ornithine transcarbamylase deficiency in girls by auxiliary liver transplantation: 
conceptual changes in a living-donor program. J Pediatr Surg. 1998 
Dec;33(12):1753-6. 
[105] Lo CM, Lo RJ, Lai CL, Fan ST, Wong J. Liver transplantation from cadaveric and living 
donors. Transplant Proc. 1996 Jun;28(3):1659-60. 
[106] Lo CM, Fan ST, Liu CL, Wei WI, Lo RJ, Lai CL, et al. Adult-to-adult living donor liver 
transplantation using extended right lobe grafts. Ann Surg. 1997 Sep;226(3):261-9; 
discussion 9-70. 
[107] Kawasaki S, Makuuchi M, Matsunami H, Hashikura Y, Ikegami T, Nakazawa Y, et al. 
Living related liver transplantation in adults. Ann Surg. 1998 Feb;227(2):269-74. 
[108] Tanaka K, Kobayashi Y, Kiuchi T. Current status of living donor liver transplantation 
in adults. Curr Opin Organ Transpl. 2000;5:74-80. 
[109] Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. 
Evolution of liver transplantation in Europe: report of the European Liver 
Transplant Registry. Liver Transpl. 2003 Dec;9(12):1231-43. 
[110] Data from US transplant organization. Available at:  
 http:// www.ustransplant.org/index.php. Accessed on March 27. 2004. 
[111] The Japanese Liver Transplantation Society. Liver Transplantation in Japan. Registery 
by the Japanese Liver Transplantation Society [Japanese]. Jpn J Transpalnt. 
2004;38:401-8. 
www.intechopen.com
 
History and Evolution of Liver Transplantation 
 
17 
[112] Lo CM, Fan ST, Liu CL, Chan JK, Lam BK, Lau GK, et al. Minimum graft size for 
successful living donor liver transplantation. Transplantation. 1999 Oct 
27;68(8):1112-6. 
[113] Fan ST, Lo CM, Liu CL, Yong BH, Chan JK, Ng IO. Safety of donors in live donor liver 
transplantation using right lobe grafts. Arch Surg. 2000 Mar;135(3):336-40. 
[114] Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, et al. 
Calculation of child and adult standard liver volume for liver transplantation. 
Hepatology. 1995 May;21(5):1317-21. 
[115] Sugawara Y, Makuuchi M, Kaneko J, Kokudo N. MELD score for selection of patients 
to receive a left liver graft. Transplantation. 2003 Feb 27;75(4):573-4. 
[116] Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et 
al. MELD and PELD: application of survival models to liver allocation. Liver 
Transpl. 2001 Jul;7(7):567-80. 
[117] Inomata Y, Uemoto S, Asonuma K, Egawa H. Right lobe graft in living donor liver 
transplantation. Transplantation. 2000 Jan 27;69(2):258-64. 
[118] Wachs ME, Bak TE, Karrer FM, Everson GT, Shrestha R, Trouillot TE, et al. Adult 
living donor liver transplantation using a right hepatic lobe. Transplantation. 1998 
Nov 27;66(10):1313-6. 
[119] Bak T, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, et al. Adult-to-adult 
living donor liver transplantation using right-lobe grafts: results and lessons 
learned from a single-center experience. Liver Transpl. 2001 Aug;7(8):680-6. 
[120] Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent 
hepatitis B after liver transplantation. Transplantation. 2003 Feb 15;75(3 Suppl):S41-
4. 
[121] Lee S, Park K, Hwang S, Lee Y, Choi D, Kim K, et al. Congestion of right liver graft in 
living donor liver transplantation. Transplantation. 2001 Mar 27;71(6):812-4. 
[122] Gyu Lee S, Min Park K, Hwang S, Hun Kim K, Nak Choi D, Hyung Joo S, et al. 
Modified right liver graft from a living donor to prevent congestion. 
Transplantation. 2002 Jul 15;74(1):54-9. 
[123] Leelaudomlipi S, Sugawara Y, Kaneko J, Matsui Y, Ohkubo T, Makuuchi M. 
Volumetric analysis of liver segments in 155 living donors. Liver Transpl. 2002 
Jul;8(7):612-4. 
[124] Sugawara Y, Makuuchi M, Takayama T, Mizuta K, Kawarasaki H, Imamura H, et al. 
Liver transplantation using a right lateral sector graft from a living donor to her 
granddaughter. Hepatogastroenterology. 2001 Jan-Feb;48(37):261-3. 
[125] Sugawara Y, Makuuchi M, Takayama T, Imamura H, Kaneko J. Right lateral sector 
graft in adult living-related liver transplantation. Transplantation. 2002 Jan 
15;73(1):111-4. 
[126] Lee S, Hwang S, Park K, Lee Y, Choi D, Ahn C, et al. An adult-to-adult living donor 
liver transplant using dual left lobe grafts. Surgery. 2001 May;129(5):647-50. 
[127] Lee SG, Hwang S, Park KM, Kim KH, Ahn CS, Lee YJ, et al. Seventeen adult-to-adult 
living donor liver transplantations using dual grafts. Transplant Proc. 2001 Nov-
Dec;33(7-8):3461-3. 
[128] Horslen SP, Fox IJ. Hepatocyte transplantation. Transplantation. 2004 May 
27;77(10):1481-6. 
[129] Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of 
human disease. Semin Liver Dis. 1999;19(1):39-48. 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
18 
[130] Shafritz DA, Dabeva MD. Liver stem cells and model systems for liver repopulation. 
Journal of hepatology. 2002 Apr;36(4):552-64. 
[131] Gupta S. Hepatocyte transplantation. J Gastroenterol Hepatol. 2002 Dec;17 Suppl 
3:S287-93. 
[132] Fox IJ, Roy-Chowdhury J. Hepatocyte transplantation. Journal of hepatology. 2004 
Jun;40(6):878-86. 
[133] Afzelius BA, Schoental R. The ultrastructure of the enlarged hepatocytes induced in 
rats with a single oral dose of retrorsine, a pyrrolizidine (Senecio) alkaloid.  
J Ultrastruct Res. 1967 Oct 31;20(5):328-45. 
[134] Mito M, Kusano M, Kawaura Y. Hepatocyte transplantation in man. Transplant Proc. 
1992 Dec;24(6):3052-3. 
[135] Arkadopoulos N, Chen SC, Khalili TM, Detry O, Hewitt WR, Lilja H, et al. 
Transplantation of hepatocytes for prevention of intracranial hypertension in pigs 
with ischemic liver failure. Cell Transplant. 1998 Jul-Aug;7(4):357-63. 
[136] Nagata H, Ito M, Shirota C, Edge A, McCowan TC, Fox IJ. Route of hepatocyte 
delivery affects hepatocyte engraftment in the spleen. Transplantation. 2003 Aug 
27;76(4):732-4. 
[137] Mito M, Kusano M, Onishi T, Saito T, Ebata H. Hepatocellular transplantation --
morphological study on hepatocytes transplanted into rat spleen. Gastroenterol 
Jpn. 1978;13(6):480-90. 
[138] Ito M, Nagata H, Yamamoto T, Yoshihara D, Fox IJ, Miyakawa S. Intrasplenic 
hepatocyte transplantation prolonged the survival in Nagase analbuminemic rats 
with liver failure induced by common bile duct ligation. Cell Transplant. 
2007;16(5):547-53. 
[139] Kobayashi N, Ito M, Nakamura J, Cai J, Hammel JM, Fox IJ. Treatment of carbon 
tetrachloride and phenobarbital-induced chronic liver failure with intrasplenic 
hepatocyte transplantation. Cell Transplant. 2000 Sep-Oct;9(5):671-3. 
[140] Makowka L, Rotstein LE, Falk RE, Falk JA, Langer B, Nossal NA, et al. Reversal of 
toxic and anoxic induced hepatic failure by syngeneic, allogeneic, and xenogeneic 
hepatocyte transplantation. Surgery. 1980 Aug;88(2):244-53. 
[141] Platt JL. New directions for organ transplantation. Nature. 1998 Apr 30;392(6679 
Suppl):11-7. 
[142] Nagata H, Ito M, Cai J, Edge AS, Platt JL, Fox IJ. Treatment of cirrhosis and liver failure 
in rats by hepatocyte xenotransplantation. Gastroenterology. 2003 Feb;124(2):422-
31. 
[143] Ramirez P, Chavez R, Majado M, Munitiz V, Munoz A, Hernandez Q, et al. Life-
supporting human complement regulator decay accelerating factor transgenic pig 
liver xenograft maintains the metabolic function and coagulation in the nonhuman 
primate for up to 8 days. Transplantation. 2000 Oct 15;70(7):989-98. 
[144] Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M. Inducible site-
directed recombination in mouse embryonic stem cells. Nucleic Acids Res. 1996 Feb 
15;24(4):543-8. 
www.intechopen.com
Liver Transplantation - Basic Issues
Edited by Prof. Hesham Abdeldayem
ISBN 978-953-51-0016-4
Hard cover, 418 pages
Publisher InTech
Published online 15, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book covers a wide spectrum of topics including history of liver transplantation, ischemia-reperfusion
injury, immunology of liver transplantation, viral hepatitis and liver transplantation, other indications for liver
transplantation, prognostic factors and perioperative period. The authors of the chapters are experts in their
respective fields. They are proponents covering different aspects of liver transplantation and come from many
centers across the world. The interdisciplinary approach and the authority of the contributors resulted in a
valuable reference to anyone interested in developing a global view in liver transplantation including medical
students, residents, fellows, nurses, and practicing physicians and surgeons as well as researchers in the field
of liver transplantation.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ayman Azzam (2012). History and Evolution of Liver Transplantation, Liver Transplantation - Basic Issues,
Prof. Hesham Abdeldayem (Ed.), ISBN: 978-953-51-0016-4, InTech, Available from:
http://www.intechopen.com/books/liver-transplantation-basic-issues/history-and-evolution-of-liver-
transplantation
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
